Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: Pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials

JACC: Cardiovascular Interventions

Volumn 4, Issue 10, 2011, Pages 1104-1115

  Planer, David ^a   Smits, Pieter C ^c   Kereiakes, Dean J ^b   Kedhi, Elvin ^c   Fahy, Martin ^a   Xu, Ke ^a   Serruys, Patrick W ^d   Stone, Gregg W ^a  

^a Department of Medicine   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c Maasstad Hospital   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

acute coronary syndrome; drug eluting stent(s); everolimus; paclitaxel; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EVEROLIMUS; PACLITAXEL; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; DEVICE; DIABETES MELLITUS; DRUG ELUTING STENT; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONFIDENCE INTERVALS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PACLITAXEL; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 80054966940     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.06.018     Document Type: Article

References (28)

1. A.J. Kirtane, A. Gupta, and S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
2. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
3. L. Mauri, T.S. Silbaugh, and P. Garg Drug-eluting or bare-metal stents for acute myocardial infarction N Engl J Med 359 2008 1330 1342
4. A. Kastrati, A. Dibra, and C. Spaulding Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction Eur Heart J 28 2007 2706 2713 (Pubitemid 350139205)
5. G.W. Stone, A.J. Lansky, S.J. Pocock HORIZONS-AMI Trial Investigators Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction N Engl J Med 360 2009 1946 1959
6. Y. Li, R. Torguson, and A.I. Syed Effect of drug-eluting stents on frequency of repeat revascularization in patients with unstable angina pectoris or non-ST-elevation myocardial infarction Am J Cardiol 104 2009 1654 1659
7. Y. Nakagawa What is the effectiveness of drug-eluting stents in the treatment of ST-elevation myocardial infarction?Should drug-eluting stents be indicated for patients with acute coronary syndrome? Circ J 74 2010 2225 2231
8. K. Inoue Drug-eluting stents are not indicated for patients with acute coronary syndromeshould drug-eluting stents be indicated for patients with acute coronary syndrome? Circ J 74 2010 2232 2238
9. B.E. Claessen, M.A. Beijk, and V. Legrand Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
10. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342 (Pubitemid 352001347)
11. M. Terashima, S. Rathore, and Y. Suzuki Accuracy and reproducibility of stent-strut thickness determined by optical coherence tomography J Invasive Cardiol 21 2009 602 605
12. G.W. Stone, M. Midei, W. Newman SPIRIT III Investigators Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V everolimus Eluting Coronary stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 2009 680 686
13. G.W. Stone, M. Midei, W. Newman SPIRIT III Investigators Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
14. G.W. Stone, A. Rizvi, W. Newman SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
15. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
16. Y. Onuma, N. Kukreja, N. Piazza Interventional Cardiologists of the Thoraxcenter (2000 to 2007) The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry J Am Coll Cardiol 54 2009 269 276
17. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
18. D.E. Cutlip, S. Windecker, R. Mehran Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
19. R.T. Lee, and P. Libby The unstable atheroma Arterioscler Thromb Vasc Biol 17 1997 1859 1867 (Pubitemid 28057082)
20. J.S. Kim, C. Fan, and D. Choi Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study Int J Cardiol 146 2011 341 346
21. G. Nakazawa, A.V. Finn, and M. Joner Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study Circulation 118 2008 1138 1145
22. A. Farb, and A.B. Boam Stent thrombosis reduxthe FDA perspective N Engl J Med 356 2007 984 987 (Pubitemid 46376798)
23. H. Kelbaek, L. Thuesen, S. Helqvist DEDICATION Investigators Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial Circulation 118 2008 1155 1162
24. G.W. Stone, S.G. Ellis, L. Cannon TAXUS V Investigators Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223 (Pubitemid 41352109)
25. J.C. Lin, S.L. Tiong, and C.Y. Chen Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization J Biomater Sci Polym Ed 11 2000 701 714
26. T.-Y. Liu, W.-C. Lin, L.-Y. Huang, S.-Y. Chen, and M.-C. Yang Surface characteristics and hemocompatibility of PAN/PVDF blend membranes Polym Adv Technol 16 2005 413 419 (Pubitemid 40707112)
27. A. Schomig, A. Dibra, and S. Windecker A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease J Am Coll Cardiol 50 2007 1373 1380 (Pubitemid 47449734)
28. C. Kaiser, S. Galatius, P. Erne BASKET-PROVE Study Group Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319